The in vitro activity of WY-49605 (SUN5555) (WY) was compared with those of cefaclor, cefixime, and amoxicillin-clavulanic acid against 2,958 consecutive clinical isolates from five medical centers and 402 respiratory pathogens from 18 other facilities. Most members of the family Enterobacteriaceae were inhibited by WY (MIC at which 50% of the isolates are inhibited [MIC 50 ], <2.0 g/ml). MIC 90 s of >8.0 g/ml were observed for Enterobacter cloacae, Serratia spp., and Proteus mirabilis. WY was the most active drug against methicillin-susceptible Staphylococcus aureus (MIC 90 , 0.12 g/ml) and other coagulase-negative staphylococci (MIC 90 , 4.0 g/ml). The four drugs were not active against nonenteric gram-negative bacilli, methicillinresistant Staphylococcus aureus, and Staphylococcus haemolyticus. At 2.0 g/ml, WY inhibited 82% of Enterococcus faecalis strains and was equal to or superior to the other drugs against streptococci, Haemophilus influenzae, and Moraxella catarrhalis.
The penem antibiotics, as a class, exhibit many positive properties such as a broad antimicrobial spectrum, a high level of resistance to hydrolysis by bacterial ␤-lactamases, and a high affinity for penicillin-binding proteins. However, their usefulness has been limited because of a short half-life in plasma due to hydrolysis by renal dipeptidases and other undesirable side effects (1, 10) . Although lacking in activity against Pseudomonas species, the penem class of compounds has remarkable antibacterial activity, and that has encouraged continued interest in developing new penems that could be useful for the treatment of serious infections. WY-49605 (also called SUN5555, SY5555, or ALP-201) (WY) is an oral penem with reported broad antibacterial activity (2-4, 6, 7, 9) and susceptibility to metabolism by renal dehydropeptidase. The hydrolysis of WY in rat lung or kidney homogenates is inhibited by cilastatin, an inhibitor of dehydropeptidase I (8) .
(This work was presented in part at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Fla., 1994 .)
The present study characterizes the in vitro activity of WY compared with the activities of cefaclor, cefixime, and amoxicillin-clavulanic acid. WY was furnished by Wyeth-Ayerst Research, Philadelphia, Pa. The other three oral beta-lactam antimicrobial agents were obtained from their respective U.S. drug manufacturers. The microorganisms represented all consecutively isolated strains that were selected for routine susceptibility tests during a 1-to 2-month period at each of five different medical centers. Additional studies were performed at the Clinical Microbiology Institute with respiratory pathogens (e.g., Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pyogenes, and Streptococcus pneumoniae) that had recently been collected from 18 different medical centers within the United States.
All six centers performed broth microdilution tests by following the procedure outlined by the National Committee for Clinical Laboratory Standards (5). Microdilution trays (Prepared Media Laboratories, Tualatin, Oreg.) contained cation-adjusted Mueller-Hinton broth with doubling dilutions of WY, cefaclor, cefixime, and amoxicillin-clavulanic acid (at a 2:1 ratio). The microdilution trays were prepared at one time, distributed to the participating facilities, and stored at Ϫ60ЊC or colder until used. For testing the respiratory pathogens, the broth was supplemented with NAD (15 g/ml) and 2 to 3% lysed horse blood. Standard control strains were tested throughout the studies, and the results demonstrated methodologic comparability among laboratories.
The results of testing 1,388 members of the family Enterobacteriaceae and 336 other nonenteric gram-negative bacilli are in Table 1 . Against Citrobacter freundii, Enterobacter aerogenes, Enterobacter cloacae, and Morganella morganii, WY was superior to the other study drugs, with MICs at which 90% of the isolates were inhibited that were 8-to 32-fold lower. Both WY and cefixime demonstrated greater activity than the other drugs against Klebsiella oxytoca, Escherichia coli, Serratia species, and Providencia species, while all four drugs were equally active against Citrobacter diversus, Klebsiella pneumoniae, and Salmonella species. Against the Proteus species, WY was more active than cefaclor and amoxicillin-clavulanic acid but less active than cefixime. All four drugs had little activity against nonenteric gram-negative bacilli.
The results of testing 1,234 gram-positive cocci are in Table  2 . Against Enterococcus faecalis isolates, WY was more active Table  3 . Streptococcus pneumoniae isolates with a decreased susceptibility to penicillin (MIC, Ն0.12 g/ml) also demonstrated diminished susceptibility to the other beta-lactam drugs tested. WY was the most potent antimicrobial agent against this group of pneumococci. All four drugs were active against penicillinsusceptible Streptococcus pneumoniae and all Streptococcus pyogenes isolates. WY, cefixime, and amoxicillin-clavulanic acid were active against both ␤-lactamase-producing and non-␤-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis. Cefaclor was less active than the other three drugs.
The penem compound WY is a broadly active antibacterial agent. Its in vitro activity was greater than those of cefaclor and cefixime and similar to that of amoxicillin-clavulanic acid against gram-positive organisms and respiratory pathogens. Like other penems, WY had little activity against Pseudomonas spp. and other nonenteric gram-negative bacilli.
The clinical relevance of this in vitro activity of WY will depend on its pharmacology. If WY can overcome the problems associated with earlier penem antibiotics (1, 10) , it should be useful for the treatment of a wide range of bacterial infections. 
